en · de · es · fr · pt
creatine-notes.peptides6579.com › Topic › Chemical Identity And Naming — Quick Reference

Chemical Identity And Naming — Quick Reference

By Editorial Desk · published 2026-02-07 · last reviewed 2026-03-08 · Topic

If you have been reading about Research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.

Chemical Identity and Naming

Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.

The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.

Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.

Dihexa Background and Research Context

The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.

Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.

Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.

Dihexa at a glance

PropertyValueNotes
Chemical classSynthetic peptide analogModeled on angiotensin IV; not a natural hormone.
Common synonymsDihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amideNaming conventions differ across vendors and papers.
CAS Registry Number1401708-83-6Listed in some chemical databases; verify against primary sources.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
SolubilitySoluble in DMSO; limited in waterOrganic stock solutions are common in laboratory settings.

Mechanism And Laboratory Characterization

The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.

Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.

Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.

Related pages on this site

Laboratory Handling and Quality Control

In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.

Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.

Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.

Supporting material

The longest word in Toki Pona is kijete­san­takalu (15 letters), which was proposed in 2009 as an April Fools' joke by the language's creator Sonja Lang as a word for any animal of the Procyonidae family, which includes raccoons and related species. The word has since entered into common use, and it has become common to define kijete­san­takalu more broadly as any animal from the Musteloidea superfamily. In 2019 James Flear designed a glyph for kijete­san­takalu in Toki Pona's Sitelen Pona writing system, which has become a popular icon within the Toki Pona community. As a minimalistic isolating constructed language, most words in Toki Pona are much shorter, the median being 4 letters. The longest words featured in the 2014 book Toki Pona: The Language of Good, Lang's first official Toki Pona publication, are the 7-letter words kepeken ("to use, by means of") and sitelen ("symbol, picture"). The list of proposed country names in the same book also mentions ma Papuwa­nijukini ("Papua New Guinea"), which includes a 14-letter proper adjective.

Other memberships include the African Development Bank, East African Community, Group of 77, Intergovernmental Authority on Development, International Bank for Reconstruction and Development, International Civil Aviation Organization, International Development Association, International Finance Corporation, Non-Aligned Movement, World Federation of Trade Unions and World Meteorological Organization.

a similar tropane alkaloid content), include the Hyoscyameae, containing such well-known toxic species as Hyoscyamus niger and Atropa belladonna, the Solandreae containing the genus Solandra ("chalice vines") and the Mandragoreae, named for the famous Mandragora officinarum, most of which are considered traditional witches' herbs and poisons.

== Career == In 2001, Burke started a tenure track role as an assistant professor at St. Francis Xavier University in 2001, and was promoted to associate professor with Tenure in 2004. In 2008, he left his academia career to start his first business. He applied his research to create a new line of sports nutrition products encompassing protein powders, energy capsules, and muscle-enhancing supplements tailored for professional athletes. In 2013 his company, Rivalus was acquired by Nutrivo. In 2017, Burke started working on a sustainable technology to decrease food waste and conserve nutrients in fruits and vegetables which would have otherwise been discarded. In 2018, he partnered with former NHL hockey player TJ Galiardi to launch Outcast Foods which is a sustainable technology-based company aimed at upcycling discarded fruits and vegetables bound for landfills. He served as the CEO of Outcast Foods till the end of 2021. In the same year he received the EY Entrepreneur of the Year for Atlantic Canada. Burke returned to academia in 2023 as an Industry Professor at McMaster University to help the university set up a makerspace and develop a curriculum for Entrepreneurship and Innovation.

Sources: en.wikipedia.org

Supporting material

An experiment comparing the permeability of quantum dots coated in polyethylene glycol (PEG), PEG-amine, and carboxylic acid concluded the PEG and PEG-amine surface groups allowed for the greatest penetration of particles. The carboxylic acid coated particles did not penetrate past the stratum corneum.

==== Other physical effects ==== The effects can also include loss of appetite, hyperactivity, dilated pupils, flushed skin, excessive sweating, increased movement, dry mouth and teeth grinding (potentially leading to condition informally known as meth mouth), headache, rapid breathing, high body temperature, diarrhea, constipation, blurred vision, dizziness, twitching, numbness, tremors, dry skin, acne, and pale appearance. Long-term methamphetamine abuse compounds these effects; xerodermia may lead to the development of sores on the skin, as well as compulsive scratching due to pruritis and/or formication. Numerous deaths related to methamphetamine overdoses have been reported. Additionally, "[p]ostmortem examinations of human tissues have linked use of the drug to diseases associated with aging, such as coronary atherosclerosis and pulmonary fibrosis", which may be caused "by a considerable rise in the formation of ceramides, pro-inflammatory molecules that can foster cell aging and death."

=== PIDDosome === PIDD-CC serves as a nucleating agent for the assembly of a complex with the dual adaptor protein RAIDD, which plays a pivotal role in the recruitment and activation of CASP2, potentially triggering apoptotic pathways. This assembly is widely recognized as the PIDDosome. In contrast, signaling pathways involving PIDD-C are primarily linked to the activation of NF-κB, thereby enhancing cell survival. In response to DNA damage, PIDD-C undergoes translocation to the nucleus, where it forms a complex with RIP1 and the NF-κB essential modulator (NEMO, also known as IKBKG), collectively termed the NEMO-PIDDosome. The term "PIDDosome" is commonly used to refer to a multiprotein complex that is made up of p53-induced death domain protein 1 (PIDD1), the bipartite linker protein CRADD (also known as RAIDD), and the inactive precursor of the caspase family endopeptidase, called caspase-2.

Sources: en.wikipedia.org

Notes from published material

== Synthesis == The biosynthesis of monoglycosylceramides requires a direct transfer of the carbohydrate moiety from a sugar-nucleotide, such as uridine 5-diphosphate(UDP)-galactose, or UDP-glucose to the ceramide unit. The glycosyl-transferase catalyzed reaction results in an inversion of the glycosidic bond stereochemistry, changing from α →β. Synthesis of galactosylceramide, and glucosylceramide occurs on the lumenal surface of the endoplasmic reticulum, and on the cytosolic side of the early Golgi membranes respectively.

On 1 July 2020, it was announced that CJNG hitman Jaime Tafolla Ortega, a.k.a. "El Alacran" (The Scorpion), was arrested on 28 June 2020. According to a statement released by the Mexican Attorney General's Office, he is suspected of gunning down Judge Uriel Villegas Ortiz and his wife, Veronica Barajas, on 16 June 2020 and leading 29 April 2020 abduction of Colima state Representative Anel Bueno Sanchez, whose body was found in a clandestine grave on 2 June 2020. Judge Villegas had gained notoriety in 2018 when he ordered the transfer of Rubén Oseguera from a jail in Oaxaca to a maximum security prison in Jalisco. A second suspect was arrested with Tafolla, though he has not yet been charged. On 15 November 2021, Rosalinda González Valencia was recaptured in Zapopan, Jalisco. The Mexican Ministry of Defense released a statement describing her arrest as "a significant blow to the financial structure of organized crime in the state", with evidence pointing to her role in "the illicit financial operation of an organized crime group." At the time, five of her brothers and two of her children were all now incarcerated as well. A Oseguera brother was still incarcerated as well. In December 2023, Rosalinda was given a five year prison sentence after being convicted for failing to disclose transactions of a car wash she owned in Puerto Vallarta, Jalisco. However, she was given an early release in February 2025. On 20 December 2022, El Mencho's brother Antonio Oseguera, alias "El Tony Montana," was captured while in possession of weapons in a suburb of Guadalajara.

MS1 data refers mainly to the isotope pattern of the compound. Due to the natural isotopic distributions of the elements, several peaks in the mass spectrum correspond to the same type of sample molecule, reflecting its isotope pattern. MS2 data refers to the fragmentation pattern of the compound. MS2 is also known as tandem mass spectrometry or MS/MS. The statistical model of SIRIUS and the machine learning model of CSI:FingerID were trained on MS2 spectra created by collision-induced dissociation (CID), as commonly applied in LC-MS/MS experiments. SIRIUS expects both, MS1 and MS2 spectra, as input. Omitting the MS1 data is possible, but it will make the analysis more time-consuming and can lead to poorer results. SIRIUS and CSI:FingerID have been trained on a wide variety of data, including data from different instrument types. Certain aspects of the mass spectra are important to successfully process the data:

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.

Is dihexa the same as angiotensin IV?

No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.

How is dihexa named in chemical databases?

It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.

What is dihexa?

Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.

Network